摘要
目的:探讨恩替卡韦联合安珐特胶囊治疗慢性乙型肝炎(CHB)的临床疗效。方法:60例CHB患者随机分为两组,治疗组30例患者口服恩替卡韦片,0.5 mg/次,1次/d,同时口服安珐特胶囊,80mg/次,3次/d。对照组30例患者单服恩替卡韦片,0.5mg/次,1次/d,均连用48周。结果:两组患者治疗前后肝功能指标ALT、AST、Alb差异有统计学意义(P<0.05),TBil差异无统计学意义(P>0.05);治疗组患者HBe Ag转阴率为50.0%,HBeAg血清学转换率为33.3%,HBV DNA转阴率为83.3%,略高于对照组的43.3%、26.7%、80.0%,差异无统计学意义(P>0.05)。两组患者治疗后的肝纤维化指标HA、LN、PC-Ⅲ、IV-C均有下降,但治疗组改善程度优于对照组,差异有统计学意义(P<0.05)。结论:恩替卡韦联合安珐特胶囊治疗CHB在改善患者肝功能、肝纤维化程度方面优于单用恩替卡韦。
Objective： To investigate the therapeutic efficacy of entecavir combined with Anfate capsule in the treatment of chronic hepati- tis B （CHB）. Methods： Totally 60 patients with HBeAg-positive CHB were randomized divided into treatment group （ n = 30） and control group （n = 30）. The patients in the treatment group were administered with ET~ 0.5mg once daily and Anfate capsule 80mg third daily for 48 weeks, while the patients in the control group were only administered with ETV 0.5 mg once daily for 48 weeks. Results ： There were sig- nificant differences in alanine aminotransferase,aspartate aminotransferase and albumin between the two groups before and after treatment（P 〈 0.05 ） ; while, there was no difference in Total bilirubin （ P 〉 0.05 ）. The treatment group HBeAg negative rate was 50%, HBeAg serocon- version rate was 33.3%, The negative rate of HBVDNA was 83.3%, Slightly higher than the control group（43.3% ,26.7% ,80.0% ） ,The differences were not statistically significant（P 〉 0.05）. Comparison of liver fibrosis indexes HA,LN, PC-Ⅲ, IV-C before and after treatment in two groups, The improvement of the treatment group was better than that of the control group, The differences were statistically significant （ P 〈0.05 ）. Conclusion： Entecavir combined with Anfate capsule had a better effects in improvement of liver function, liver fibrosis than monotherapy with entecavir in patients with chronic hepatitis B.
出处
《中西医结合肝病杂志》
CAS
2017年第4期220-221,227,共3页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
